ASCO Reporter

News and Updates from the American Society of Clinical Oncology Annual Meeting


Oncology

VA Care Not Timely in Early Lung Cancer; But Did It Matter?

Multiple organizations have recommended timely treatment for patients with lung cancer.

Oncology

Cabozantinib May Help Overcome Checkpoint Inhibitor Resistance in GU Cancers

The treatment armamentarium for renal cell carcinoma and other genitourinary cancers continues to expand.

Oncology

VA Study Indicates That Location Matters in Colon Cancer Survival

More than 95,000 Americans develop colon cancer, making it the third most common cancer in the U.S., excluding skin cancers.


More for You

April 2019

Combat, Not Deployment, Appears to Increase Risk of New-Onset Asthma

BETHESDA, MD—Many reports have suggested that servicemembers who deployed to Iraq and Afghanistan developed respiratory illnesses at higher-than-expected rates, but study results looking at increased rates of asthma have been mixed. A new study by... View Article

April 2019

VA Continues Efforts to Reduce Drug Diversion; Focuses on Opiates

WASHINGTON—In the past two years, the VA has implemented a nine-step process to minimize drug diversion, but cases continue to slip through. In December 2018, the VA’s Office of the Inspector General reported two instances... View Article

April 2019

Overcoming Radiation Resistant Prostate Cancer

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article

April 2019

JAK Enzymes Can Treat Leukemia, Lymphoma

NASHVILLE, TN—Precision oncology prescribes the use of molecularly-targeted therapy directed by identification of genomic alterations. A new study suggested the approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, such as... View Article

April 2019

Response of Veterans to PD-1 Checkpoint Inhibitors

RENO, NV—The clinical outcomes and the incidence of adverse events for programmed death-1 checkpoint inhibitors in cancer patients at a VA clinic were different from the data that have been published, according to a new... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up